Etigilimab is under clinical development by Mereo Biopharma Group and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Etigilimab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Etigilimab (OMP-313M32) is under development for the treatment of advanced or metastatic solid tumors includes sarcoma, uveal melanoma, germ cell cancer, epithelial ovarian cancer, peritoneal cancer and fallopian tube cancer, head and neck cancer, adenocarcinoma of the gastroesophageal junction, esophageal cancer, gastric cancer, cervical cancer, triple negative breast cancer, endometrial cancer, pancreatic cancer, anal cancer, hepatocellular cancer, colorectal cancer and non-small cell lung cancer. It is administered intravenously. The therapeutic candidate is an IgG1 monoclonal antibody. It acts by targeting TIGIT.
Mereo Biopharma Group overview
Mereo Biopharma Group is a specialty bio-pharmaceutical company. The company develops novel medicines for the treatment of rare and specialty diseases. It’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome and BCT-197, and Etigilimab (MPH-313), which treats solid tumors. Mereo Biopharma Group also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotropic hypogonadism and its Navicixizumab (OMP-305B83) is in Phase 1 clinical trial which treats platinum-resistant ovarian cancer. The company collaborates with biotechnology and pharmaceutical companies. Mereo Biopharma Group is headquartered in London, England, the UK.
For a complete picture of Etigilimab’s drug-specific PTSR and LoA scores, buy the report here.